| Primary information |
|---|
| sequence ID | Seq_7252 |
| Peptide sequence | SKITHRIHWESASLLR |
| CancerPDF_ID | CancerPDF_ID9482, CancerPDF_ID9607, |
| PMID | 26379225,21533267 |
| Protein Name | Complement C3,Complement C3 |
| UniprotKB Entry Name | CO3_HUMAN,CO3_HUMAN |
| Fluid | Plasma,Serum |
| M/Z | 1934.07,484.28 |
| Charge | NA,4 |
| Mass (in Da) | NA,NA |
| fdr | NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS |
| Peptide Identification technique | MALDI-TOF/TOF,LC/MS/MS |
| Quantification Technique | NA,Multiple Reaction Monitoring |
| Labelled/Label Free | Label Free,Label Free |
| FDR | NA,1.49 |
| CancerPDF_ID | CancerPDF_ID9482, CancerPDF_ID9607, |
| p-Value | NA,NA |
| Software | MASCOT (v 2.3),MASCOT |
| Length | 16,16 |
| Cancer Type | Colorectal cancer,Lung adenocarcinoma |
| Database | UniprotKB,Swissprot Database (57.4) |
| Modification | NA,NA |
| Number of Patients | "94 patients with CRC, 23 with liver metastasis from CRC (histologically defined) and 34 subjects, which underwent colonoscopy and resulted negative",62 lung adenocarcinoma and 30 healthy control |
| Regulation | "Low expression in control, adenoma, early,late CRC and much more lower in liver metastasis group.","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | NA,MRM-based validation of 19 candidates |
| Sensitivity | NA,NA |
| Specificity | NA,NA |
| Accuracy | NA,NA |
| Peptide Atlas | NA |
| IEDB | 533899
|